|

REGN10597 Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since August 2026

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Regeneron Pharmaceuticals2

Indications

  • Cancer2
  • Clear Cell Renal Cell Carcinoma (ccRCC)1
  • Fallopian Tube Cancer1
  • Primary Peritoneal Cancer1
  • Advanced Solid Tumors1

Birmingham, Alabama1 trial

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

The University of Alabama at Birmingham

Phase 2

Los Angeles, California1 trial

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

USC Norris Comprehensive Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.